Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186281 | 1.00 | KMT2A (0.37) | KMT2AMEN1AGTR2TP53POLB | |
| SCHEMBL4138695 | 0.94 | MEN1 (0.37) | KMT2AMEN1AGTR2TP53POLB | |
| SCHEMBL4138694 | 0.94 | MEN1 (0.37) | KMT2AMEN1AGTR2TP53POLB | |
| SCHEMBL5252503 | 0.90 | MRGPRX4 (0.33) | KMT2AMEN1AGTR2MRGPRX4ALDH1A1 | |
| SCHEMBL5187346 | 0.85 | CA1 (0.38) | HTTDHFRALDH1A1 | |
| SCHEMBL4135216 | 0.85 | MEN1 (0.37) | KMT2AMEN1AGTR2TP53POLB | |
| SCHEMBL4135218 | 0.85 | MEN1 (0.37) | KMT2AMEN1AGTR2TP53POLB | |
| SCHEMBL4696338 | 0.84 | MEN1 (0.33) | KMT2AMEN1 | |
| SCHEMBL4145058 | 0.82 | MEN1 (0.35) | KMT2AMEN1AGTR2TP53POLB | |
| SCHEMBL4145056 | 0.82 | MEN1 (0.35) | KMT2AMEN1AGTR2TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | KMT2A 3643/4885MEN1 154/4885AGTR2 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.